InnoCare Pharma (9969) Q3 2024 earnings summary

Executive summary

• Orelabrutinib sales rose 75.5% year-over-year in Q3 2024, with year-to-date sales reaching RMB693 million, up 45% year-over-year, driving strong commercial and financial performance.

• Gross profit margin improved to 86.0% for the first three quarters of 2024, reflecting operational efficiency and improved revenue mix.

• Net loss for Jan–Sep 2024 narrowed by 47.1% year-over-year to RMB285 million, supported by sales growth, cost efficiency, and favorable FX impact.

• Robust cash and related balances of RMB7.8 billion as of September 30, 2024, provide flexibility for R&D and strategic investments.

• Significant clinical progress across hemato-oncology and autoimmune disease pipelines, including multiple phase 3 trials and regulatory submissions.

Financial highlights

• Q3 2024 drug sales reached RMB479 million (+76.3% yoy); Jan–Sep 2024 drug sales were RMB695 million (+45.2% yoy).

• Net loss for Jan–Sep 2024 was RMB285 million, down from RMB539 million in the prior year period.

• Gross profit margin rose to 86.0% for Jan–Sep 2024, up from 81.2% year-over-year.

• R&D expenses for Jan–Sep 2024 were RMB615 million, up 11.9% year-over-year.

• Selling expense ratio declined, reflecting improved cost efficiency.

Outlook and guidance

• Full-year sales growth guidance raised from 35% to over 45% due to strong performance.

• No specific timetable for breakeven; focus remains on R&D investment and commercialization expansion.

• Orelabrutinib expected to continue growth with expanded indications and NRDL coverage.

• Future launches planned for tafasitamab (2025) and solid tumor products (2026).

• Remaining IPO and subscription proceeds to be fully utilized by 2026–2027, mainly for clinical trials, product launches, and R&D.